News Center

• Aug. 30

  2022

  “MOXIFLOXACIN HYDROCHLORIDE AND SODIUM CHLORIDE INJECTION” OBTAINS DRUG REGISTRATION APPROVAL

  The“Moxifloxacin Hydrochloride and Sodium Chloride Injection has obtained drug registration approval granted by the National Medical Products Administration of the People’s Republic of China, and is deemed to have passed the consistency evaluation of quality and efficacy of generic drugs.

• Aug. 30

  2022

  CLASS 1 NEW DRUG “PRUSOGLIPTIN TABLETS” MEETS PREDEFINED ENDPOINTS IN THE PIVOTAL CLINICAL TRIALS

  The class 1 new drug “Prusogliptin Tablets” (“DBPR108 Tablets”) of CSPC has met the predefined endpoints in two pivotal clinical trials for the treatment of type 2 diabetes.

• Aug. 30

  2022

  SELECTIVE NTRK AND ROS1 DUAL INHIBITOR “SYHX2009” OBTAINS CLINICAL TRIAL APPROVAL

  “SYHX2009” (the “Product”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China.

• Jul. 27

  2022

  Congratulations on the Successful Approval and Launch of Mitoxantrone Liposome

  Mitoxantrone hydrochloride liposome for injection (10ml:10mg), our key innovative product, has been launched successfully on January 11. This product is a self-developed anti-tumor nano-drug of CSPC as well as the first mitoxantrone nano-drug launched in the world

• Jul. 20

  2022

  CSPC advances to the 25th Place in the Pharma 1000 List

  Recently, Torreya published The Pharma 1000: Top Global Pharmaceutical Company Report. The Report ranks the world's top 1,000 pharmaceutical companies by valuation and provides the latest developments of the global pharmaceutical industry in 2021. CSPC was included in the list again, ranking 25th and taking second place among the Chinese pharmaceut

• Jul. 13

  2022

  CSPC's COVID-19 Vaccine Approved for Clinical Trials

  On April 3, 2022, CSPC Pharmaceutical Group Co., Ltd. (Stock code 1093. HK) announced that the COVID-19 mRNA vaccine SYS6006 ("the product") developed by the Group was approved by the National Medical Products Administration for clinical trials in China.